Cargando…
Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263200/ https://www.ncbi.nlm.nih.gov/pubmed/35812270 http://dx.doi.org/10.1016/j.ekir.2022.06.008 |
| _version_ | 1784742676397031424 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9263200 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92632002022-07-09 Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 Kidney Int Rep Corrigendum Elsevier 2022-07-05 /pmc/articles/PMC9263200/ /pubmed/35812270 http://dx.doi.org/10.1016/j.ekir.2022.06.008 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Corrigendum Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title | Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title_full | Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title_fullStr | Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title_full_unstemmed | Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title_short | Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188 |
| title_sort | corrigendum to inaba m, une y, ikejiri k, et al. “dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in japan—a phase 2 randomized trial.” kidney int rep. 2022;7:177–188 |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263200/ https://www.ncbi.nlm.nih.gov/pubmed/35812270 http://dx.doi.org/10.1016/j.ekir.2022.06.008 |